GlobeNewswire
-
New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
12/11/2026 -
Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
12/11/2026 -
BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
12/11/2026 -
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
12/11/2026 -
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
12/11/2026 -
InspireMD Announces Proposed Public Offering
12/11/2026 -
Voting Rights and Shares Capital of the Company
12/11/2026 -
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
12/11/2026 -
BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
12/11/2026 -
Serotonin Anti-Aging Centers Founder Puts a Physician-Led Longevity Clinic Inside New York Sports Club
12/11/2026 -
Aristocrat Plastic Surgery Expands Access to Preservé Breast Augmentation Under Trainer Dr. Kevin Tehrani, Who Has Performed More Than 5,000 Breast Procedures, Reinforcing Its Position as a Destination for Breast Augmentation in NYC
12/11/2026 -
Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical Development Program into the United States
12/11/2026 -
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
12/11/2026 -
Sanofi: Information concerning the total number of voting rights and shares - October 2026
12/11/2026 -
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2026
12/11/2026 -
Ally Medical ER Wins Midsize Company Category for Fourth Straight Year in Austin American-Statesman Top Workplaces
12/11/2026 -
Ennature Biopharma Advances Curcumin Formulation With Water-Dispersible Maxicuma
12/11/2026 -
New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)
12/11/2026 -
QUAD A Announces Dr. Monte Jay Goldstein as President of Its Board of Directors
12/11/2026
Pages